Перевести на Переведено сервисом «Яндекс.Перевод»

Bellerophon Therapeutics LLC

Link
www.bellerophon.com
Country
USA
Headquarters
184 Liberty Corner Road, Suite 302 Warren, NJ 07059
Ticker
NASDAQ:BLPH
Description

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company has two programs in development. The first program, INOpulse, is based on its pulsatile nitric oxide delivery device. The Company is developing two product candidates under its INOpulse program: one for the treatment of pulmonary arterial hypertension (PAH) and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase II development. Its second program is bio absorbable cardiac matrix (BCM), which is in a placebo-controlled clinical trial. The Company is developing BCM for the prevention of cardiac remodeling, which leads to congestive heart failure following an ST-segment elevated myocardial infarction (STEMI).